Cara Therapeutics (CARA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

CARA Stock Forecast

Cara Therapeutics stock forecast is as follows: an average price target of $14.50 (represents a 3070.09% upside from CARA’s last price of $0.46) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

CARA Price Target

The average price target for Cara Therapeutics (CARA) is $14.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $1.00. This represents a potential 3070.09% upside from CARA's last price of $0.46.

CARA Analyst Ratings

Buy

According to 4 Wall Street analysts, Cara Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CARA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 1 'Hold' (25.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).

Cara Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 13, 2024	Sumant Kulkarni	Canaccord Genuity	$1.00	$0.68	47.17%	118.63%
Jun 12, 2024	Annabel Samimy	Stifel Nicolaus	$1.00	$0.68	47.17%	118.63%
May 10, 2022	Oren Livnat	H.C. Wainwright	$30.00	$9.23	225.03%	6458.81%
Mar 03, 2022	Joseph Stringer	Needham	$26.00	$11.08	134.66%	5584.30%

The latest Cara Therapeutics stock forecast, released on Jun 13, 2024 by Sumant Kulkarni from Canaccord Genuity, set a price target of $1.00, which represents a 47.17% increase from the stock price at the time of the forecast ($0.68), and a 118.63% increase from CARA last price ($0.46).

Cara Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$1.00
Last Closing Price	$0.46	$0.46	$0.46
Upside/Downside	-100.00%	-100.00%	118.63%

In the current month, the average price target of Cara Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cara Therapeutics's last price of $0.46. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 13, 2024	Needham	Buy	Buy	Hold
Jun 13, 2024	H.C. Wainwright		Neutral	Downgrade
Jun 13, 2024	Needham	Buy	Hold	Downgrade
Jun 13, 2024	Canaccord Genuity	Underperform	Negative	Downgrade
May 14, 2024	Needham	Buy	Buy	Hold
May 14, 2024	Canaccord Genuity	Underperform	Underperform	Hold
Mar 28, 2024	Needham	Buy	Buy	Hold
Mar 28, 2024	Canaccord Genuity	Underperform	Underperform	Hold
Mar 05, 2024	Needham	Buy	Buy	Hold
Dec 19, 2023	Piper Sandler	Buy	Buy	Hold
Nov 14, 2023	Piper Sandler	Overweight	Neutral	Downgrade
Mar 07, 2023	Needham	Buy	Buy	Hold
Mar 07, 2023	Piper Sandler	Overweight	Overweight	Hold
Mar 03, 2022	Needham	Buy	Buy	Hold

Cara Therapeutics's last stock rating was published by Needham on Jun 13, 2024. The company gave CARA a "Buy" rating, the same as its previous rate.

Cara Therapeutics Financial Forecast

Cara Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	-	$3.00M	$4.87M	$6.93M	$6.17M	$3.26M	$10.81M	$23.00M	$4.79M	$821.00K	$20.27M	-	$1.94M	$112.09M	$9.27M	$5.63M	$8.09M	$4.51M	$5.79M	$5.21M	$4.38M	$911.00K	$7.00K
Avg Forecast	$600.00K	$800.00K	$1.00M	$1.20M	$1.69M	$2.02M	$1.18M	$1.68M	$9.42M	$9.95M	$6.50M	$4.89M	$14.50M	$8.84M	$21.11M	$2.64M	$1.46M	$15.59M	$2.59M	$3.02M	$5.97M	$4.73M	$5.01M	$4.71M	$5.39M	$4.84M	$3.06M	$3.29M	$832.27K	$7.54K
High Forecast	$895.06K	$1.19M	$1.49M	$1.79M	$2.52M	$3.01M	$1.75M	$1.68M	$15.78M	$14.84M	$9.69M	$7.30M	$21.63M	$8.84M	$21.11M	$2.64M	$1.46M	$15.59M	$2.59M	$3.02M	$5.97M	$4.73M	$5.01M	$4.71M	$5.39M	$4.84M	$3.06M	$3.29M	$998.72K	$9.04K
Low Forecast	$429.18K	$572.25K	$715.31K	$858.37K	$1.21M	$1.44M	$841.20K	$1.68M	$4.39M	$7.12M	$4.65M	$3.50M	$10.37M	$8.84M	$21.11M	$2.64M	$1.46M	$15.59M	$2.59M	$3.02M	$5.97M	$4.73M	$5.01M	$4.71M	$5.39M	$4.84M	$3.06M	$3.29M	$665.82K	$6.03K
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	4	4	7	4	3	7	9	19
Surprise %	-	-	-	-	-	-	-	-	0.32%	0.49%	1.07%	1.26%	0.22%	1.22%	1.09%	1.82%	0.56%	1.30%	-	0.64%	18.76%	1.96%	1.12%	1.72%	0.84%	1.19%	1.70%	1.33%	1.09%	0.93%

Cara Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.68M, with a low forecast of $1.68M, and a high forecast of $1.68M. CARA's average Quarter revenue forecast represents a -43.95% decrease compared to the company's last Quarter revenue of $3.00M (Dec 23).

Cara Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	4	4	7	4	3	7	9	19
EBITDA	-	-	-	-	-	-	-	-	$-32.61M	$-28.03M	$-31.48M	$-27.59M	$-31.31M	$-23.84M	$-4.41M	$-27.85M	$-33.32M	$-951.00K	$-30.68M	$-23.24M	$78.72M	$-16.59M	$-25.20M	$-29.00M	$-28.73M	$-33.12M	$-23.14M	$-22.00M	$-22.11M	$-10.11M
Avg Forecast	$-475.03K	$-633.37K	$-791.72K	$-950.06K	$-1.34M	$-1.60M	$-931.06K	$-25.10M	$-7.46M	$-7.88M	$-5.14M	$-26.85M	$-11.48M	$-7.00M	$-16.71M	$-28.71M	$-1.15M	$-12.34M	$-2.05M	$-27.96M	$-4.73M	$-3.74M	$-3.97M	$-29.00M	$-4.26M	$-3.83M	$-2.42M	$-22.75M	$-20.02M	$-10.83M
High Forecast	$-339.79K	$-453.06K	$-566.32K	$-679.59K	$-957.27K	$-1.14M	$-665.99K	$-20.08M	$-3.47M	$-5.64M	$-3.68M	$-21.48M	$-8.21M	$-7.00M	$-16.71M	$-22.97M	$-1.15M	$-12.34M	$-2.05M	$-22.37M	$-4.73M	$-3.74M	$-3.97M	$-23.20M	$-4.26M	$-3.83M	$-2.42M	$-18.20M	$-16.02M	$-8.66M
Low Forecast	$-708.64K	$-944.85K	$-1.18M	$-1.42M	$-2.00M	$-2.38M	$-1.39M	$-30.12M	$-12.50M	$-11.75M	$-7.67M	$-32.21M	$-17.13M	$-7.00M	$-16.71M	$-34.45M	$-1.15M	$-12.34M	$-2.05M	$-33.56M	$-4.73M	$-3.74M	$-3.97M	$-34.80M	$-4.26M	$-3.83M	$-2.42M	$-27.30M	$-24.03M	$-12.99M
Surprise %	-	-	-	-	-	-	-	-	4.37%	3.56%	6.12%	1.03%	2.73%	3.41%	0.26%	0.97%	28.86%	0.08%	14.95%	0.83%	-16.64%	4.43%	6.35%	1.00%	6.74%	8.64%	9.57%	0.97%	1.10%	0.93%

2 analysts predict CARA's average Quarter EBITDA for Mar 21 to be $-27.96M, with a high of $-22.37M and a low of $-33.56M. This is -135.53% lower than Cara Therapeutics's previous annual EBITDA (Dec 20) of $78.72M.

Cara Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	4	4	7	4	3	7	9	19
Net Income	-	-	-	-	-	-	-	-	$-32.34M	$-28.03M	$-31.48M	$-25.68M	$-29.37M	$-22.52M	$-3.94M	$-27.59M	$-33.38M	$-1.01M	$-30.75M	$-23.30M	$78.91M	$-16.51M	$-25.07M	$-28.92M	$-28.61M	$-32.84M	$-22.96M	$-21.96M	$-22.20M	$-10.69M
Avg Forecast	$-10.97M	$-12.61M	$-11.52M	$-10.97M	$-10.79M	$-13.16M	$-15.03M	$-25.16M	$-24.46M	$-28.52M	$-29.52M	$-26.91M	$160.47M	$-22.52M	$-14.31M	$-28.78M	$-27.99M	$-21.14M	$-30.01M	$-28.04M	$19.94M	$-32.68M	$-36.43M	$-28.92M	$-36.06M	$-31.68M	$-33.60M	$-22.72M	$-20.10M	$-11.46M
High Forecast	$-6.91M	$-7.95M	$-7.25M	$-6.91M	$-5.99M	$-8.29M	$-9.47M	$-20.13M	$-23.60M	$-17.96M	$-18.60M	$-21.53M	$192.57M	$-22.52M	$-14.31M	$-23.02M	$-27.99M	$-21.14M	$-30.01M	$-22.43M	$19.94M	$-32.68M	$-36.43M	$-23.14M	$-36.06M	$-31.68M	$-33.60M	$-18.17M	$-16.08M	$-9.16M
Low Forecast	$-17.98M	$-20.68M	$-18.88M	$-17.98M	$-14.98M	$-21.58M	$-24.63M	$-30.19M	$-25.75M	$-46.75M	$-48.40M	$-32.29M	$128.38M	$-22.52M	$-14.31M	$-34.53M	$-27.99M	$-21.14M	$-30.01M	$-33.65M	$19.94M	$-32.68M	$-36.43M	$-34.71M	$-36.06M	$-31.68M	$-33.60M	$-27.26M	$-24.12M	$-13.75M
Surprise %	-	-	-	-	-	-	-	-	1.32%	0.98%	1.07%	0.95%	-0.18%	1.00%	0.28%	0.96%	1.19%	0.05%	1.02%	0.83%	3.96%	0.51%	0.69%	1.00%	0.79%	1.04%	0.68%	0.97%	1.10%	0.93%

Cara Therapeutics's average Quarter net income forecast for Mar 21 is $-28.04M, with a range of $-33.65M to $-22.43M. CARA's average Quarter net income forecast represents a -135.53% decrease compared to the company's last Quarter net income of $78.91M (Dec 20).

Cara Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	4	4	7	4	3	7	9	19
SG&A	-	-	-	-	-	-	-	-	$6.59M	$6.75M	$7.54M	$6.86M	$6.43M	$6.91M	$7.54M	$9.31M	$11.48M	$5.85M	$5.62M	$6.37M	$6.66M	$5.22M	$5.41M	$4.56M	$4.62M	$4.23M	$4.99M	$3.91M	$2.40M	$2.45M
Avg Forecast	$524.62K	$699.49K	$874.36K	$1.05M	$1.48M	$1.76M	$1.03M	$1.47M	$8.24M	$8.70M	$5.68M	$4.28M	$13.54M	$7.73M	$18.45M	$2.31M	$1.28M	$13.63M	$2.27M	$2.64M	$5.22M	$4.13M	$4.38M	$4.56M	$4.71M	$4.24M	$2.67M	$2.88M	$727.71K	$6.59K
High Forecast	$782.61K	$1.04M	$1.30M	$1.57M	$2.20M	$2.63M	$1.53M	$1.47M	$13.80M	$12.98M	$8.47M	$6.38M	$16.25M	$7.73M	$18.45M	$2.31M	$1.28M	$13.63M	$2.27M	$2.64M	$5.22M	$4.13M	$4.38M	$5.47M	$4.71M	$4.24M	$2.67M	$2.88M	$873.25K	$7.91K
Low Forecast	$375.26K	$500.35K	$625.44K	$750.52K	$1.06M	$1.26M	$735.51K	$1.47M	$3.84M	$6.22M	$4.06M	$3.06M	$10.83M	$7.73M	$18.45M	$2.31M	$1.28M	$13.63M	$2.27M	$2.64M	$5.22M	$4.13M	$4.38M	$3.65M	$4.71M	$4.24M	$2.67M	$2.88M	$582.16K	$5.27K
Surprise %	-	-	-	-	-	-	-	-	0.80%	0.78%	1.33%	1.60%	0.47%	0.89%	0.41%	4.04%	9.00%	0.43%	2.48%	2.41%	1.27%	1.26%	1.23%	1.00%	0.98%	1.00%	1.87%	1.36%	3.30%	371.32%

Cara Therapeutics's average Quarter SG&A projection for Mar 24 is $1.47M, based on 2 Wall Street analysts, with a range of $1.47M to $1.47M. The forecast indicates a -77.65% fall compared to CARA last annual SG&A of $6.59M (Dec 23).

Cara Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 17	Mar 16
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	4	4	7	4	3	7	9	19
EPS	-	-	-	-	-	-	-	-	$-0.59	$-0.00	$-0.00	$-0.48	$-0.55	$-0.42	$-0.07	$-0.52	$-0.63	$-0.02	$-0.61	$-0.47	$1.68	$-0.35	$-0.54	$-0.62	$-0.61	$-0.74	$-0.58	$-0.56	$-0.81	$-0.39
Avg Forecast	$-0.20	$-0.23	$-0.21	$-0.20	$-0.20	$-0.24	$-0.27	$-0.40	$-0.45	$-0.52	$-0.54	$-0.51	$-0.34	$-0.41	$-0.26	$-0.55	$-0.51	$-0.39	$-0.55	$-0.57	$0.36	$-0.60	$-0.67	$-0.60	$-0.66	$-0.58	$-0.61	$-0.58	$-0.67	$-0.45
High Forecast	$-0.13	$-0.14	$-0.13	$-0.13	$-0.11	$-0.15	$-0.17	$-0.25	$-0.43	$-0.33	$-0.34	$-0.32	$-0.22	$-0.41	$-0.26	$-0.55	$-0.51	$-0.39	$-0.55	$-0.57	$0.36	$-0.60	$-0.67	$-0.60	$-0.66	$-0.58	$-0.61	$-0.58	$-0.54	$-0.36
Low Forecast	$-0.33	$-0.38	$-0.34	$-0.33	$-0.27	$-0.39	$-0.45	$-0.65	$-0.47	$-0.85	$-0.88	$-0.84	$-0.56	$-0.41	$-0.26	$-0.55	$-0.51	$-0.39	$-0.55	$-0.57	$0.36	$-0.60	$-0.67	$-0.60	$-0.66	$-0.58	$-0.61	$-0.58	$-0.80	$-0.54
Surprise %	-	-	-	-	-	-	-	-	1.32%	0.00%	0.00%	0.94%	1.60%	1.02%	0.28%	0.94%	1.23%	0.05%	1.11%	0.82%	4.62%	0.59%	0.81%	1.03%	0.93%	1.28%	0.94%	0.97%	1.21%	0.87%

According to 2 Wall Street analysts, Cara Therapeutics's projected average Quarter EPS for Mar 21 is $-0.57, with a low estimate of $-0.57 and a high estimate of $-0.57. This represents a -134.07% decrease compared to CARA previous annual EPS of $1.68 (Dec 20).

Cara Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
CARA	Cara Therapeutics	$0.25	$14.50	5700.00%	Buy
XXII	22nd Century Group	$4.37	$82.50	1787.87%	Buy
CRBP	Corbus Pharmaceuticals	$14.29	$57.80	304.48%	Buy

CARA Forecast FAQ

Is Cara Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Cara Therapeutics (CARA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of CARA's total ratings.

What is CARA's price target?

Cara Therapeutics (CARA) average price target is $14.5 with a range of $1 to $30, implying a 3070.09% from its last price of $0.457. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cara Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CARA stock, the company can go up by 3070.09% (from the last price of $0.457 to the average price target of $14.5), up by 6458.81% based on the highest stock price target, and up by 118.63% based on the lowest stock price target.

Can Cara Therapeutics stock reach $1?

CARA's average twelve months analyst stock price target of $14.5 supports the claim that Cara Therapeutics can reach $1 in the near future.

What are Cara Therapeutics's analysts' financial forecasts?

Cara Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.57M (high $8.97M, low $5.18M), average EBITDA is $-28.967M (high $-22.846M, low $-35.888M), average net income is $-64.133M (high $-43.875M, low $-91.381M), average SG&A $5.74M (high $7.84M, low $4.53M), and average EPS is $-1.109 (high $-0.684, low $-1.768). CARA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.6M (high $5.37M, low $2.58M), average EBITDA is $-2.85M (high $-2.039M, low $-4.252M), average net income is $-46.069M (high $-29.019M, low $-75.521M), average SG&A $3.15M (high $4.7M, low $2.25M), and average EPS is $-0.84 (high $-0.529, low $-1.377).

Did the CARA's actual financial results beat the analysts' financial forecasts?

Based on Cara Therapeutics's last annual report (Dec 2023), the company's revenue was $20.97M, which missed the average analysts forecast of $30.76M by -31.83%. Apple's EBITDA was $-121M, beating the average prediction of $-47.325M by 156.73%. The company's net income was $-119M, beating the average estimation of $-109M by 8.32%. Apple's SG&A was $27.78M, beating the average forecast of $26.89M by 3.29%. Lastly, the company's EPS was $-2.19, beating the average prediction of $-2.018 by 8.54%. In terms of the last quarterly report (Dec 2023), Cara Therapeutics's revenue was $3M, missing the average analysts' forecast of $9.42M by -68.12%. The company's EBITDA was $-32.607M, beating the average prediction of $-7.459M by 337.14%. Cara Therapeutics's net income was $-32.337M, beating the average estimation of $-24.46M by 32.20%. The company's SG&A was $6.59M, missing the average forecast of $8.24M by -20.03%. Lastly, the company's EPS was $-0.59, beating the average prediction of $-0.446 by 32.29%